Tom Kubic—an FBI veteran, former president and CEO of the Pharmaceutical Security Institute, and president of PSM’s governing board—has the experience to know that the risks of drug importation are “unacceptably high” and the potential rewards are “virtually nil.”[...]
So, what does all of this have to do with importing drugs from a friendly nation like Canada? The simple, inarguable fact is that, once we open up our drug supply, we can no longer ensure the safety of the products in it.[...]
Instead of wasting time and money on dangerous and faulty importation proposals, Congress should encourage the FDA to speed up the drug approval process and reduce the cost of program and application fees for future drug development. In 2022, the application fee for a human drug application will cost $1.6 million for drugs that don’t require clinical data and $3.1 million for medicines that do need clinical data.[...]
While working to find a way to provide relief to patients at the pharmacy counter, American politicians again look to the idea of drug importation as a possible solution. Looking at all the evidence, the Partnership for Safe Medicines believes such plans will not only make no difference in reducing patient out-of-pocket costs, but will…[...]
In this February 24, 2022 editorial published on the Connecticut Business & Industry Association’s website, Paul Pescatello reviews the practical reasons that mean that importing drugs from Canada will not lower prescription drug prices. Pescatello is the executive director of CBIA’s Bioscience Growth Council and chair of We Work for Health Connecticut.[...]
Shabbir Safdar, executive director of the Partnership for Safe Medicines, released this statement in response to President Biden’s executive order to foster competition, which favors importation of prescription drugs from Canada.[...]
ADAP Advocacy Association CEO Brandon M. Macsata wrote this editorial, which appeared on the AIDS Drug Assistance Program’s website on April 1, 2021.
The Association first warned constituents that counterfeit Symtuza had been distributed to three U.S. pharmacies in December 2020, when Janssen issued an alert.[...]
The White House approved regulations for state drug importation in late state, green-lighting several states’ efforts to implement importation.
None of them is up and running yet. Check out this week’s video and post for an update.[...]